title: [The value of sequential CD 34 measurement for carrying out stem cell pheresis].
abstract: The recent significant improvement in disease-free survival in patients with certain haematological malignancies is due to high-dose chemotherapy and subsequent autologous bone marrow and/or stem cell transplantation. The proliferation and egression of stem cells into the peripheral blood must first be stimulated by defined chemotherapy and/or by administration of cytokines. However, the increase of circulating stem cells in peripheral blood is limited to only a few days. By immunologically analysing white blood cells for the expression of the surface antigen CD 34 it is possible to calculate the numbers of haematopoietic progenitor cells. Thus, besides monitoring haematopoietic recovery, the estimation of CD34+ cells in the peripheral blood can be used to indicate the optimal time point for stem cell collection. Two to four stem cell pheresis (one per day) may then yield sufficient stem cells to enable the safe and rapid reconstitution of haematopoiesis following supralethal chemotherapy.
authors.affiliation: II. Medizinische Abteilung des Donauspitals, Wien.
authors.forename: P
authors.initials: P
authors.lastname: Kier
authors.forename: K
authors.initials: K
authors.lastname: Huber
authors.forename: R
authors.initials: R
authors.lastname: Ruckser
authors.forename: K H
authors.initials: KH
authors.lastname: Habertheuer
authors.forename: K
authors.initials: K
authors.lastname: Bauer
authors.forename: P
authors.initials: P
authors.lastname: Höcker
authors.forename: M
authors.initials: M
authors.lastname: Kurz
authors.forename: E
authors.initials: E
authors.lastname: Tiefengraber
authors.forename: C
authors.initials: C
authors.lastname: Sebesta
authors.forename: W
authors.initials: W
authors.lastname: Hinterberger
mesh_terms: D015703:Antigens, CD / Q000032:analysis*; D018952:Antigens, CD34; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001781:Blood Component Removal / Q000379:methods*; D003114:Colony-Forming Units Assay / Q000379:methods*; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D016207:Cytokines / Q000008:administration & dosage*; D004921:Erythropoietin / Q000008:administration & dosage; D005434:Flow Cytometry / Q000379:methods*; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000008:administration & dosage; D006410:Hematopoiesis / Q000187:drug effects; D006412:Hematopoietic Stem Cells / Q000187:drug effects / Q000276:immunology*; D006801:Humans
chemical_list: D015703:Antigens, CD; D018952:Antigens, CD34; D000970:Antineoplastic Agents; D016207:Cytokines; D004921:Erythropoietin; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D003520:Cyclophosphamide